Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 8/20 | 0.42 |
| ▸ | TNF | P01375 | 8/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 5/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177738 | 0.88 | TNF (0.39) | ESR2TNFPOLBGAANPSR1 | |
| SCHEMBL3192060 | 0.85 | TNF (0.35) | TNFPOLBGAANPSR1HDAC6 | |
| SCHEMBL3188070 | 0.84 | PRKCA (0.38) | GAANPSR1LMNA | |
| SCHEMBL5263692 | 0.82 | ESR2 (0.41) | ESR2TNFESR1HDAC6HSD17B13 | |
| SCHEMBL3429086 | 0.79 | ESR2 (0.36) | ESR2POLB | |
| SCHEMBL664005 | 0.78 | HDAC6 (0.55) | TNFPOLBGAANPSR1HDAC6 | |
| SCHEMBL1012831 | 0.76 | ESR2 (0.52) | ESR2TNFPOLBGAANPSR1 | |
| SCHEMBL21177886 | 0.75 | LMNA (0.35) | ESR2TNFPOLBGAANPSR1 | |
| SCHEMBL5500566 | 0.74 | ESR1 (0.47) | ESR2TNFPOLBGAANPSR1 | |
| SCHEMBL5562061 | 0.74 | HDAC6 (0.55) | TNFPOLBHDAC6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022476-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | US | disclosed |
| EP-1836191-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006067391-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022476-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | CCNI, MKI67, TP53 | ESR2 2537/4885TNF 3198/4885POLB 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.